Provide Input

Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

lisocabtagene maraleucel (Breyanzi)

Therapeutic Area: Relapsed or refractory large B-cell lymphoma
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation

Submit Feedback

 

enfortumab vedotin (Padcev)

Therapeutic Area: Metastatic urothelial cancer
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation

Submit Feedback

 

fruquintinib (Fruzaqla)

Therapeutic Area: Metastatic colorectal cancer (mCRC)
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation

Submit Feedback

 

talquetamab (Talvey)

Therapeutic Area: Relapsed or refractory multiple myeloma
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation

Submit Feedback

 

venetoclax (Venclexta)

Therapeutic Area: Chronic lymphocytic leukemia (CLL)
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: advanced renal cell carcinoma (RCC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: advanced or metastatic
malignant pleural mesothelioma (MPM)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: large B-cell lymphoma (LBCL)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Head and neck cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Prostate cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Advanced or recurrent endometrial carcinoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Locally advanced or metastatic non-small cell lung cancer (NSCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Locally advanced or metastatic non-small cell lung cancer (NSCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: limited-stage small cell lung cancer (LS-SCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Chronic hand eczema
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: